Experimental biotech pill ENV-308 delivers an encouraging safety profile in a Phase 1 clinical trial of 88 healthy adults, according to startup biotech company Enveda. Designed to curb appetite by mimicking the body’s natural response to vigorous exercise, the daily oral tablet replicates a molecule discovered by Stanford scientists in 2022 without triggering the gastrointestinal distress or muscle loss commonly associated with blockbuster GLP-1 medications like Ozempic and Wegovy, according to company statements and trial data.
How Enveda’s ENV-308 Mimics Exercise Chemistry
The daily oral tablet replicates a molecule known as lactate phenylalanine, or Lac-Phe. According to scientific findings from Stanford researchers, the body produces Lac-Phe naturally when lactate—a chemical released by muscles during intense physical activity—combines with the amino acid phenylalanine. Once released into the bloodstream, the molecule signals the brain to reduce the drive to eat.
Natural Lac-Phe breaks down quickly in the body, preventing it from maintaining appetite suppression throughout the day. Enveda’s experimental drug aims to solve this limitation by delivering the benefits of the exercise-induced molecule in a stable, daily oral tablet, according to Viswa Colluru, the startup’s founder and CEO.
Phase 1 Clinical Trial Results and Safety Data
In the initial Phase 1 trial evaluating 88 healthy adults, researchers administered ENV-308 at varying strengths to test safety rather than weight loss. According to Enveda, participants tolerated the drug across all tested doses, displaying what the company described as an exceptional gastrointestinal safety profile.
This tolerability profile addresses a primary drawback of existing treatments. Nausea and vomiting frequently cause patients to discontinue blockbuster GLP-1 medications. Furthermore, animal studies indicate that ENV-308 preserves lean muscle mass during weight reduction and helps maintain slimmer figures after treatment stops, contrasting with the weight regain often observed when patients discontinue GLP-1 therapies.
Pro Tip: Medical researchers emphasize that pharmacological treatments like ENV-308 are still in early development.
Future Clinical Trials and Potential Combination Therapies
Researchers plan to evaluate whether ENV-308 impacts actual body weight, body composition, and leptin biology in subsequent clinical phases. Dr. Naveed Sattar, a professor of metabolic medicine at the University of Glasgow and chair of the UK’s Obesity Healthcare Goals Program, notes that patients and physicians need therapies that sustain metabolic benefits over time, calling the new mechanism of action an encouraging step toward later-stage trials.
Enveda is also exploring whether the pill can be used alongside existing GLP-1 therapies to reduce dosing frequency or mitigate side effects. Beyond weight management, the company intends to study the drug’s efficacy in treating conditions where exercise provides benefits, including migraines, inflammatory bowel disease, and polyendocrine metabolic ovarian syndrome.
Frequently Asked Questions
When will ENV-308 be available by prescription?
Prescriptions are not expected anytime soon. ENV-308 remains in early development, and researchers require years of additional trials to confirm long-term safety and efficacy before seeking Food and Drug Administration approval.
Can ENV-308 completely replace a gym membership?
No. Even if the drug successfully mimics certain metabolic effects of exercise, physical activity provides numerous additional health benefits—including improved mental health, enhanced brain function, better sleep, and reduced inflammation—that a pill cannot replicate.
How does ENV-308 differ from medications like Ozempic?
While GLP-1 medications target specific gut hormones and can cause significant gastrointestinal side effects and muscle loss, ENV-308 mimics an exercise-induced molecule called Lac-Phe, which early trials suggest preserves lean mass and offers an exceptional gastrointestinal safety profile.
What are your thoughts on exercise-mimicking pills? Do you think they will complement or change how people approach fitness? Share your thoughts in the comments below, explore our related health coverage, and subscribe to our newsletter for updates on biotechnology breakthroughs.
Related reading